The gastrointestinal (GI) segment is a growing specialty market with significant unmet needs, many of which are chronic and are often untreated. For nearly 30 years, Salix has licensed, developed and marketed innovative products to treat GI and hepatologic conditions, including hepatic encephalopathy, irritable bowel syndrome with diarrhea, traveler’s diarrhea, opioid-induced constipation and ulcerative colitis, among many others.

 

Salix